Regeneron shares rise as eczema drug sales help drugmaker post Q4 earnings beat

By Scott Kanowsky -- Shares in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) rose on Friday after the drugmaker posted better-than-expected earnings in the fourth quarter despite a dip in sales of its key eye drug.

The blockbuster medication, known as Eylea, has supported the company's performance since its release over a decade ago. In 2022, it raked in $6.27 billion in sales.

However, the temporary closure of a non-profit fund that provides patient co-pay assistance partly contributed to a 3% decline in sales of Eylea in the final three months of the year to $1.5B. The company noted that customers had also shifted to an off-label brand of Eylea, although this was deemed a "short-term" trend.

The winding down by the U.S. government of a pandemic-era drug procurement program meant that Regeneron did not book any sales from its COVID antibody cocktail as well. In the final quarter of 2021, sales of the therapy had come in at $2.3B.

But strong demand remained for the eczema drug Dupixent, which was recorded in partner Sanofi's (NASDAQ:SNY) results, helped partially offset these drops. Regeneron took home $836M in collaboration revenue from the French pharmaceutical firm, an increase of 61% year-on-year.

"The change in the Company's share of profits from commercialization of antibodies was driven by profits associated with higher Dupixent sales," Regeneron said in a statement.

As a result, total quarterly revenues of $3.4B were above Bloomberg consensus estimates of $3.12B, even though the top-line figure slumped by 31%. Profit of $12.56 per share during the period was also above expectations of $10.03 a share, according to Reuters.

In a note to clients, analysts at RBC Capital Markets said Regeneron's latest numbers were "generally in-line" with prior predictions, but flagged that "shares will likely trade near-term around less predictable Eylea dynamics."

Begin trading today! Create an account by completing our form

Privacy Notice

At One Financial Markets we are committed to safeguarding your privacy.

Please see our Privacy Policy for details about what information is collected from you and why it is collected. We do not sell your information or use it other than as described in the Policy.

Please note that it is in our legitimate business interest to send you certain marketing emails from time to time. However, if you would prefer not to receive these you can opt-out by ticking the box below.

Alternatively, you can use the unsubscribe link at the bottom of the Demo account confirmation email or any subsequent emails we send.

By completing the form and downloading the platform you agree with the use of your personal information as detailed in the Policy.

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.7% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Back to top

Office network
  • London Office
    One Financial Markets 

    1 Finsbury Market
    EC2A 2BN
    United Kingdom

    T:  + 44 ( 0 ) 203 857 2000
  • Dubai Office
    One Financial Markets 
    OT19-39 Central Park Tower
    Dubai International Finance Centre
    United Arab Emirates
    T: + 971 44 22 888

One Financial Markets is the trading name of Axi Financial Services (UK) Ltd, a company registered in England with company number 6050593. Axi Financial Services (UK) Ltd is authorised and regulated by the Financial Conduct Authority in the UK (under firm reference number 466201) and the Financial Sector Conduct Authority in South Africa (with FSP number 45784).

The information on this site is not directed at residents of the United States, Belgium, Poland or any particular country outside the UK and is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation. is owned and operated by Axi Financial Services (UK) Ltd.

Award winning broker
We have been presented with a number of awards that recognise the quality of our service and dedication to our clients :

Best FSA Regulated Broker
Saudi Money Expo

Best Education Product
Saudi Money Expo

Best Broker - Online Trading
IAIR Awards

Best Institutional Broker
Saudi Money Expo

Best FX Services Broker
CN Forex

Top International
FX Broker 2015

Saudi Money Expo

Broker of the Year
Online Trading – Middle East

IAIR Awards

Best Forex
Customer Service 2018

JFEX Awards

We accept the following payment methods: